Immuno-Oncology | Specialty

Pembrolizumab/Axitinib Improves Survival in Frontline RCC

October 19th 2018

Combining the PD-1 inhibitor pembrolizumab with the VEGF inhibitor axitinib significantly improved survival versus sunitinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

Testing Reveals Extent of Lynch Syndrome

October 16th 2018

The presence of Lynch syndrome correlates with microsatellite-instability status and DNA mismatch-repair deficiency across a variety of tumor types.

Combinations With RT May Improve Immunotherapy Response

October 16th 2018

One potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.

The Importance of Curiosity in Expanding Cancer Immunology

October 13th 2018

Jill O'Donnell-Tormey, PhD, chief executive officer, director of scientific affairs, Cancer Research Institute, discusses the importance of curiosity in expanding the role of immunology in the treatment of cancer.

Dr. Sharma Discusses Immune Checkpoint Resistance in GU Cancers

October 12th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.

Nivolumab Misses OS Endpoint in SCLC Study

October 12th 2018

Single-agent nivolumab (Opdivo) did not improve overall survival compared with standard topotecan or amrubicin, where approved, in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.

Lead Investigator Discusses Frontline Pembrolizumab in NSCLC

October 12th 2018

Gilberto Lopes, MD, discusses the KEYNOTE-042 results and ongoing developments with immunotherapy in NSCLC.

Immunotherapy in NSCLC: Audience Q&A

October 10th 2018

I-O Therapy Versus Surgery or Chemotherapy in NSCLC

October 10th 2018

PD-L1 Expression in NSCLC

October 10th 2018

Managing Pneumonitis in NSCLC

October 10th 2018

Immunotherapy in Locally Advanced NSCLC

October 10th 2018

Experience With I-O Therapies in Second-Line NSCLC

October 10th 2018

Continuing/Re-Challenging With I-O Therapy in NSCLC

October 10th 2018

Treating Relapsed/Refractory NSCLC After I-O Therapy

October 10th 2018

TMB as a Predictive Biomarker in NSCLC

October 10th 2018

Combining Chemotherapy & Immunotherapy in Squamous NSCLC

October 10th 2018

Immunotherapy + Chemotherapy in Nonsquamous NSCLC

October 10th 2018

Upfront PD-1 Inhibitor Monotherapy in Advanced NSCLC

October 10th 2018

Practical Application of Recent Clinical Data for Immunotherapy in NSCLC

October 10th 2018